BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22130035)

  • 1. Screening for cardiac risk before anthracycline administration: what are the real benefits?
    Ewer MS; Yang M; Buzdar AU
    Clin Breast Cancer; 2012 Feb; 12(1):1-3. PubMed ID: 22130035
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer drug warning.
    Johns Hopkins Med Lett Health After 50; 2012 Dec; 24(11):8. PubMed ID: 23342677
    [No Abstract]   [Full Text] [Related]  

  • 3. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there more for us to learn from oncology?: Examining the implications of anthracycline effects on the young heart.
    Sawyer DB
    Circulation; 2010 Feb; 121(5):623-5. PubMed ID: 20100976
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chemotherapeutics-induced heart failure].
    Paulides M; Wojnowski L
    Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant anthracyclines: time for a change of heart?
    O'Regan R
    Oncology (Williston Park); 2011 Feb; 25(2):140, 142. PubMed ID: 21456385
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and prevention of cardiac complications of cancer chemotherapy.
    Monsuez JJ
    Arch Cardiovasc Dis; 2012 Nov; 105(11):593-604. PubMed ID: 23177488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity.
    Garcia JA; Simvoulidis LF; Salluh JI; Hansen MH; Feres GA; Holanda GS; Souza RC; Toscano L; Soares M
    Int J Cardiol; 2007 Jun; 118(3):406-7. PubMed ID: 17028018
    [No Abstract]   [Full Text] [Related]  

  • 15. The heart of the matter.
    Portera CC; Swain SM
    J Clin Oncol; 2007 Sep; 25(25):3794-6. PubMed ID: 17664459
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.
    Cadoo K; Lowery M; McCaffrey J
    Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
    Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
    Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy.
    Oliveira GH; Qattan MY; Al-Kindi S; Park SJ
    Circ Heart Fail; 2014 Nov; 7(6):1050-8. PubMed ID: 25415958
    [No Abstract]   [Full Text] [Related]  

  • 19. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
    Nolan L; Darby A; Boleti K; Simmonds P
    Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.